DE60223718T2 - Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen - Google Patents

Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen Download PDF

Info

Publication number
DE60223718T2
DE60223718T2 DE60223718T DE60223718T DE60223718T2 DE 60223718 T2 DE60223718 T2 DE 60223718T2 DE 60223718 T DE60223718 T DE 60223718T DE 60223718 T DE60223718 T DE 60223718T DE 60223718 T2 DE60223718 T2 DE 60223718T2
Authority
DE
Germany
Prior art keywords
dementia
use according
disease
atomoxetine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60223718T
Other languages
German (de)
English (en)
Other versions
DE60223718D1 (de
Inventor
Franklin Porter Brownsburg Bymaster
Donald Richard Indianapolis GEHLERT
David Lee Whitestown MCKINZIE
Charles Renkin Indianapolis YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60223718D1 publication Critical patent/DE60223718D1/de
Publication of DE60223718T2 publication Critical patent/DE60223718T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60223718T 2001-12-11 2002-11-27 Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen Expired - Fee Related DE60223718T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
US339174P 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (2)

Publication Number Publication Date
DE60223718D1 DE60223718D1 (de) 2008-01-03
DE60223718T2 true DE60223718T2 (de) 2008-10-30

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223718T Expired - Fee Related DE60223718T2 (de) 2001-12-11 2002-11-27 Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen

Country Status (26)

Country Link
US (1) US20050009925A1 (enExample)
EP (1) EP1458368B1 (enExample)
JP (1) JP2005517647A (enExample)
KR (1) KR20040066895A (enExample)
CN (1) CN1713900A (enExample)
AU (1) AU2002352625A1 (enExample)
BR (1) BR0213581A (enExample)
CA (1) CA2467802A1 (enExample)
CO (1) CO5590907A2 (enExample)
CZ (1) CZ2004709A3 (enExample)
DE (1) DE60223718T2 (enExample)
EA (1) EA200400793A1 (enExample)
EC (1) ECSP045145A (enExample)
ES (1) ES2295435T3 (enExample)
HR (1) HRPK20040528B3 (enExample)
HU (1) HUP0402619A3 (enExample)
IL (1) IL161989A0 (enExample)
MX (1) MXPA04005716A (enExample)
MY (1) MY136367A (enExample)
NO (1) NO20042904L (enExample)
NZ (1) NZ532065A (enExample)
PL (1) PL369311A1 (enExample)
SK (1) SK2442004A3 (enExample)
TW (1) TW200300672A (enExample)
WO (1) WO2003049724A1 (enExample)
ZA (1) ZA200404274B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050049476A (ko) * 2002-08-14 2005-05-25 파마시아 앤드 업존 캄파니 엘엘씨 홍조를 치료하기 위한 레복세틴의 용도
ATE526954T1 (de) * 2003-07-28 2011-10-15 Leslie Joe Dunaway Atomoxetin zur behandlung von allergischer rhinitis und asthma
US20070105960A1 (en) * 2003-08-27 2007-05-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
DE602004014823D1 (de) * 2003-12-12 2008-08-14 Lilly Co Eli Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
WO2005105763A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
US20140249180A1 (en) * 2011-10-03 2014-09-04 National Center For Geriatrics And Gerontology Tau aggregation inhibitor
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
JP6313750B2 (ja) 2013-04-02 2018-04-18 学校法人同志社 タウ凝集阻害剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
DE60019473T2 (de) * 1999-07-01 2006-02-23 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
ATE297374T1 (de) * 1999-10-13 2005-06-15 Pfizer Prod Inc Biaryletherderivate, die als inhibitoren der monoamin-wiederaufnahme nützlich sind
US20020161002A1 (en) * 2001-01-02 2002-10-31 Mel Epstein Use of catecholamine reuptake inhibitors to enhance memory
AU2002232470B2 (en) * 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents

Also Published As

Publication number Publication date
MXPA04005716A (es) 2004-12-06
CZ2004709A3 (cs) 2004-10-13
HRP20040528A2 (en) 2004-10-31
MY136367A (en) 2008-09-30
US20050009925A1 (en) 2005-01-13
HUP0402619A2 (hu) 2005-03-29
NZ532065A (en) 2007-03-30
ES2295435T3 (es) 2008-04-16
AU2002352625A1 (en) 2003-06-23
CO5590907A2 (es) 2005-12-30
CA2467802A1 (en) 2003-06-19
ECSP045145A (es) 2004-07-23
SK2442004A3 (en) 2004-12-01
BR0213581A (pt) 2004-08-24
JP2005517647A (ja) 2005-06-16
WO2003049724A1 (en) 2003-06-19
EP1458368A1 (en) 2004-09-22
PL369311A1 (en) 2005-04-18
IL161989A0 (en) 2005-11-20
EP1458368B1 (en) 2007-11-21
TW200300672A (en) 2003-06-16
DE60223718D1 (de) 2008-01-03
HUP0402619A3 (en) 2008-04-28
ZA200404274B (en) 2005-09-13
EA200400793A1 (ru) 2004-10-28
HRPK20040528B3 (en) 2006-03-31
NO20042904L (no) 2004-09-07
CN1713900A (zh) 2005-12-28
KR20040066895A (ko) 2004-07-27

Similar Documents

Publication Publication Date Title
DE69623141T2 (de) Verwendung von Tomoxetin zur Behandlung von Hyperaktivität mit Aufmerksamkeitsstörungen
DE60223718T2 (de) Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
DE3782935T2 (de) Praeparat zur vorbeugung vor seekrankheit.
DE69507419T2 (de) Verwendung von einem Tetrahydropyridin- oder azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen
DE69819891T2 (de) Spiro chinuclidin-derivate, ihre herstellung und verwendung
DE3855323T2 (de) Galenische 2-beta-Mimetik-Formen für die per- und sublinguale Verabreichung
DE69926804T2 (de) Vorrichtungen zur behandlung und diagnose des restless leg syndroms
EP1051170A1 (de) Verwendung von substituierten aminomethyl-chromanen zur verhinderung der neuronalen degeneration und zur förderung der neuronalen regeneration
CH668184A5 (de) Verwendung von acyloxyalkanoylcholinsalzen fuer die herstellung eines mittels zur besserung und therapie von neuropsychiatrischen symptomen, die die demenz begleiten.
EP2050435B1 (de) Hustenpräparat
DE602004009079T2 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
EP0826370A1 (de) Pharmazeutische Zubereitung, die 2-Phenyl-1,2-Benzoisoelenazol-3(2H)-one enthält, für die Behandlung der Alzheimer-Krankheit
EP1461042B1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60220825T2 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
EP0035597A2 (de) Pharmazeutische Zubereitungen
DE60009315T2 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
DE69004529T2 (de) Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
DE69904206T2 (de) Verwendung von cetirizin zur vorbeugung von asthma eintritt
DE69516075T2 (de) Verwendung von einem azabicyclischen Oxadiazol- oder -Thiadiazol-Verbindung zur Behandlung von Angstzuständen
DD297557A5 (de) Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
EP0493861B1 (de) Nicotinamid-adenin-dinukleodid enthaltendes Antidepressionsmittel
DE2461570C3 (de) Arzneimittel für die Behandlung bakterieller Infektionen der Augen und/oder der Ohren und Verfahren zu ihrer Herstellung
DE10354893B4 (de) Verwendung von Desoxypeganin zur Behandlung schizophrener Psychosen
DE3432974A1 (de) Arzneimittel zur prophylaxe oder therapie der negativen shizophreniesymtome bei menschen
DE2831728A1 (de) Arzneimittel zur behandlung von kopfschmerzen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8339 Ceased/non-payment of the annual fee